GSK acquires Nuvalent for $10.6 billion to expand cancer portfolio

GSK acquired Nuvalent for $10.6 billion to expand its cancer portfolio after previously winding down the area. The move marks GSK's largest acquisition in eight years. The deal aims to reverse prior reductions in cancer-focused research and development.